Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV‐infected people on opioid agonist therapy-Reference-Cited by-同舟云学术

Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV‐infected people on opioid agonist therapy

Published:2021-04-15 Issue:6 Volume:28 Page:878-886
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Macías Juan¹^ORCID,Téllez Francisco²,Santos Ignacio³,Morano Luis E.⁴,Merino Dolores⁵,Granados Rafael⁶,Vera‐Mendez Francisco⁷,González‐Serna Alejandro¹,Campo‐Moneo Esther⁸,García‐Fraile Lucio³^ORCID,García Federico⁹^ORCID,Real Luis M.¹^ORCID,Pineda Juan A.¹,

Affiliation:

1. Infectious Diseases and Microbiology Unit Hospital Universitario de Valme Seville Spain

2. Infectious Diseases Unit Hospital Universitario de Puerto Real Department of Medicine Cadiz University Cadiz Spain

3. Infectious Diseases Unit Hospital Universitario la Princesa Madrid Spain

4. Infectious Diseases Unit Hospital Universitario Alvaro Cunqueiro Vigo Spain

5. Infectious Diseases Unit Hospital Infanta Elena Huelva Spain

6. Infectious Diseases Unit Hospital Universitario de Gran Canaria Dr. Negrín Gran Canaria Spain

7. Infectious Diseases Unit Hospital General Universitario Santa Lucía Cartagena Spain

8. Centro Penitenciario Puerto III Puerto Santa María Cadiz Spain

9. Microbiology Service Hospital Universitario San Cecilio Granada Spain

Funder

Instituto de Salud Carlos III

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13496

Reference20 articles.

1. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review

2. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study

3. Organization WH.Combating hepatitis B and C to reach elimination by 2030.https://wwwwhoint/hepatitis/publications/hep‐elimination‐by‐2030‐brief/en/2016.

4. Disparities in uptake of direct‐acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting

5. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection